Sreelakshmi Kolli

About Sreelakshmi Kolli

Sreelakshmi Kolli (age 50) has served on Zimmer Biomet’s Board since 2021. She is Executive Vice President and Chief Product and Digital Officer at Align Technology, with prior leadership roles spanning IT, digital transformation, and product lifecycle across Align since 2003; she previously held technical lead roles at Citadon and Accenture. She holds an M.S. in Computer Applications from National Institute of Technology, Trichy, India, and completed the Stanford Executive Program; her core credentials include digital technology, AI/ML, data privacy, and product innovation in regulated medtech environments .

Past Roles

External Roles

Board Governance

• Independence: The Board determined Kolli is independent under NYSE and company guidelines .
• Committee assignments: Audit Committee member; Chair, Quality, Regulatory & Technology (QR&T) Committee .
• Meeting cadence and attendance: In 2024, the Board met 6 times; standing committees met 22 times; all directors attended at least 75% of the meetings of the Board and committees on which they served .
• QR&T scope (chair responsibilities): Oversight of product quality and safety, regulatory compliance (including FDA), technology and innovation strategies, product pipeline, and AI/ML applications in medical technology .

Fixed Compensation

2024 Stock Awards detail:

Director retainer structure (annual):

• Director retainer: $110,000; QR&T Chair retainer: $15,000; paid quarterly with mandatory deferral provisions .

Performance Compensation

• Zimmer Biomet does not tie non-employee director compensation to performance metrics; director equity is time-based with mandatory deferral (RSUs vest immediately but settle after deferral; DSUs settle after board service ends) .
• No discretionary bonus or performance-linked pay disclosed for directors .

Other Directorships & Interlocks

• Limit on other directorships: Non-employee directors who are executive officers of other public companies are limited to serving on a total of three public company boards (including their employer’s board and Zimmer Biomet’s); Kolli’s roles are within these limits .

Expertise & Qualifications

• Deep expertise in digital and emerging technologies, AI/ML, data privacy, product innovation, strategic planning, and operations in highly regulated global medtech .
• Adds domain alignment to QR&T oversight (AI/ML, technology strategy, quality systems, regulatory compliance) .

Equity Ownership

Insider trades (Form 4 – Deferred Compensation accruals):

Governance Assessment

• Strengths:

  • Independence, majority voting standard, and strong committee oversight; Kolli chairs QR&T, directly aligned with her digital/AI expertise—positive for technological diligence and product quality oversight .
  • Mandatory equity deferral (RSUs and DSUs) enhances long-term alignment; hedging/pledging prohibited—reduces misalignment risk .
  • Board and committee attendance thresholds met; executive sessions of independent directors at each regular meeting—supports robust oversight .

• Watch items:

  • Time commitments: Executive role at Align plus another public board (Intuitive) alongside ZBH; within company policy limits but warrants monitoring for workload/engagement risk in fast-evolving tech/quality domains .
  • Ownership alignment: Beneficial ownership is modest (<1% of shares outstanding); alignment primarily via deferred director equity rather than material direct stakes .

• Conflicts/related-party:

  • No related-party transactions disclosed involving Kolli; Audit Committee reviews and must approve any such transactions .

• Overall signal:

  • Digital/AI credentials paired with QR&T chair role and independent status bolster investor confidence in oversight of Zimmer Biomet’s integrated digital and robotic technology portfolio and quality/compliance posture .